Immuron Ltd — Capital/Financing Update 2015

Jan 5, 2015

==> picture [201 x 57] intentionally omitted <==

Immuron Signs a License Agreement with Immune Biologics for the Development and Commercialisation of IMM-124E for Alcohol Toxicity

Melbourne, Australia – 6[th] January 2015: Australian biopharmaceutical company Immuron Limited (ASX: IMC) is pleased to announce that it has entered into an agreement with Immune Biologics Pty Ltd for the development and commercialisation of IMM-124E for the treatment of short-term alcohol-induced liver toxicity.

Under the agreement, Immune Biologics will carry out clinical trials designed to test the efficacy of IMM124E for the prevention and/or treatment and/or amelioration of short-term alcohol-induced liver toxicity. The principle underlying these studies is that the anti-LPS activity of IMM-124E is the same underlying mechanism that governs the treatment of both non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH), thus enabling the testing and use of IMM-124E in this third short-term clinical indication.

Pending a successful outcome of the clinical trials to be undertaken by Immune Biologics, Immuron will sell the IMM-124E to Immune Biologics under a worldwide license for the use of IMM-124E specifically for toxicity associated with short-term alcohol intake.

Immune Biologics Pty Ltd is a company associated with Mr Peter Anastasiou, Immuron’s largest shareholder through various entities related to him.

Immuron Chief Executive Officer Amos Meltzer said: “Immuron’s clinical focus with IMM-124E is the development of prescription products for chronic liver diseases such as NASH and ASH. The opportunity to license out the use of IMM-124E for a new indication, with the prospect of early revenues, is another illustration of the versatility of Immuron’s platform technology. This Agreement is also a vote of confidence by Immuron’s largest shareholder in Immuron’s technology.”

Contacts:

Amos Meltzer Chief Executive Officer +61 (0)437 587 680

Investor Relations Amanda Loh, Buchan Consulting +61 (0)3 9866 4722

Websites: www.immuron.com and www.travelan.com

About Immuron

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron’s technology platform products all have a very high safety profile. The company’s current products and product candidates address infectious diseases of the gastrointestinal tract as well as chronic diseases. Immuron has an on-market product, Travelan®, for preventing travellers’ diarrhoea. Immuron also has a phase 2 clinical product candidate for the treatment of inflamed fatty liver disease, known as Non-Alcoholic Steatohepatitis or NASH. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel) and Monash University (Australia).

www.immuron.com

Suite 1, 1233 High Street Armadale, Victoria AUSTRALIA 3143

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735

ABN: 80 063 114 045